Why I’m scooping up more WRAP
Why I'm buying more Wrap Tech (WRAP) after earnings. Plus, is it time to buy Disney (DIS) on the pullback? … The surprising sector boosting AI… A quick AI earnings rundown… And a 10x opportunity in the biotech space.
A recap of our first-ever Curzio One Wealth Forum
Best moments from our inaugural conference: Hyperscalers are in dire need of power… How it feels to get "Bolawrapped"... Wonder Woman's stunt double… From biotech to luxury candy: Deals for One members… And how to join Curzio One.
Rate cuts are coming: What it means for your portfolio
How the Fed's about-face on interest rates will impact the market. Plus, avoid this common mistake when shorting stocks… The AT&T (T)/EchoStar (SATS) deal… Has Eli Lilly (LLY) bottomed? … And Nvidia's (NVDA) earnings.
Why biotech is about to see M&A heat up
An M&A wave is coming in biotech. Plus, the U.S. vs. China: Who needs a deal more? … The Fed’s B.S. move… Time to buy small caps? … Buy these cryptos… And the next CoreWeave (CRWV)?
5 solid stocks trading at huge discounts
Disney (DIS) is in survival mode… Germany's big move… 5 beaten-down stocks to watch… Don't overlook this tech name... What's driving Autozone (AZO) higher? … This biotech stock's pullback is overdone… And a trade on tomorrow's crypto summit.
Apple is flashing major warning signs
What to expect from the "Magnificent 7" in 2024… The biggest risks to the market... Why you need to be extremely wary of Apple (AAPL)… And the left-for-dead sector poised to soar this year.
Why ‘hope’ is a horrible investment strategy
Andrew Horowitz of The Disciplined Investor explains why the Fed is hell-bent on hiking rates... Why you shouldn't pin your hopes on the Fed... and his advice for this market. Plus, Andrew's new fetish could make money in the metaverse.
A financial phenomenon you can’t afford to ignore…
Marc Lichtenfeld of The Oxford Club explains why the pullback is great for income investors... How to accelerate the compounding process—a phenomenon most investors ignore... How to find bonds for income... And a solid risk/reward setup in biotech.
Peak inflation is here… and I’ll tell you how to play it
The Fed bank stress test results... Signs inflation is peaking... And why the worst of the selloff is behind us. Plus, earnings red flags... and how to meet Frank in Las Vegas.
One biotech’s 80% single-day plunge: A case study for investors
Biotech Kodiak Sciences (KOD) plunged 80% in one day after a major drug trial setback. It’s a critical lesson on expectations… and the benefits of contrarian investing.
Get ready for the next “Roaring ’20s”
Genia shares why the economy is set to bounce back with a vengeance… three sectors to benefit from the recovery… and how to invest in “the Roaring ’20s 2.0” for maximum profit.
Why Pfizer is a better buy than Johnson & Johnson
In part three of David Cohne’s valuation series, he walks us through a comparison of two popular pharma stocks using five valuation metrics. Whenever you're deciding between two stocks to buy, keep this guide handy...
Did you buy these 5 tech stocks yet?
Genia highlights five of her best market calls... and why most are still fantastic buys at today’s levels. As you’ll see, it pays to follow Genia’s work…
Search by
